近乎完全预防！礼来“减肥神药”新突破：糖尿病风险狂降94%

格隆汇08-20

当地时间周二，礼来公司（Eli Lilly）在糖尿病和肥胖治疗领域取得了令人瞩目的进展，其研发的减肥药替尔泊肽(tirzepatide)在临床试验中显示出显著的疗效：与安慰剂相比，替尔泊肽将糖尿病前期、肥胖或超重的成年人患2型糖尿病的风险降低了94%。消息影响下，截至发稿，礼来涨超4%，竞争对手诺和诺德(NVO.US)下跌0.16%。糖尿病风险锐减94%据悉，这项名为SURMOUNT-1的研究，...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460888376?lang=zh_CN&edition=full","thumbnail":"https://img3.gelonghui.com/557ab-728a9cf3-41e1-40a7-9042-f4d5d0f8c65c.jpg?guru_height=960&guru_width=1280","is_english":false,"pubTime":"2024-08-20 22:47","share_image_url":"https://static.laohu8.com/6b8fa6424aebe95f6781d04ef17a1852","id":"2460888376","market":"hk","top_or_hot":-1,"title":"近乎完全预防！礼来“减肥神药”新突破：糖尿病风险狂降94%","media":"格隆汇","content":"<div>\n<p>当地时间周二，礼来公司（Eli Lilly）在糖尿病和肥胖治疗领域取得了令人瞩目的进展，其研发的减肥药替尔泊肽(tirzepatide)在临床试验中显示出显著的疗效：与安慰剂相比，替尔泊肽将糖尿病前期、肥胖或超重的成年人患2型糖尿病的风险降低了94%。消息影响下，截至发稿，礼来涨超4%，竞争对手诺和诺德(NVO.US)下跌0.16%。糖尿病风险锐减94%据悉，这项名为SURMOUNT-1的研究，...</p>\n\n<a href=\"https://www.gelonghui.com/p/939963\">网页链接</a>\n\n</div>\n","source":"gelonghui_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>近乎完全预防！礼来“减肥神药”新突破：糖尿病风险狂降94%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n近乎完全预防！礼来“减肥神药”新突破：糖尿病风险狂降94%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-20 22:47 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.gelonghui.com/p/939963><strong>格隆汇</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>当地时间周二，礼来公司（Eli Lilly）在糖尿病和肥胖治疗领域取得了令人瞩目的进展，其研发的减肥药替尔泊肽(tirzepatide)在临床试验中显示出显著的疗效：与安慰剂相比，替尔泊肽将糖尿病前期、肥胖或超重的成年人患2型糖尿病的风险降低了94%。消息影响下，截至发稿，礼来涨超4%，竞争对手诺和诺德(NVO.US)下跌0.16%。糖尿病风险锐减94%据悉，这项名为SURMOUNT-1的研究，...</p>\n\n<a href=\"https://www.gelonghui.com/p/939963\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0289739699.SGD","symbol_name":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","start_time":0,"source_url":"https://www.gelonghui.com/p/939963","article_id":"2460888376","we_media_id":null,"thumbnails":["https://img3.gelonghui.com/557ab-728a9cf3-41e1-40a7-9042-f4d5d0f8c65c.jpg?guru_height=960&guru_width=1280"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2460888376","pubTimestamp":1724165254,"sourceInfo":{"source_id":"gelonghui_highlight","name":"格隆汇"},"weMediaInfo":null,"summary":"诺和诺德再遭冲击","collect":0,"end_time":0,"defaultTopTitle":"gelonghui.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LLY":"礼来","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","BK4516":"特朗普概念","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","BK4532":"文艺复兴科技持仓","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4534":"瑞士信贷持仓","BK4585":"ETF&股票定投概念","LU0097036916.USD":"贝莱德美国增长A2 USD","LU0466842654.USD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"A\" (USD) ACC","IE00BK4W5L77.USD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (USD) ACC","LU0689472784.USD":"安联收益及增长基金Cl AM AT Acc","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0320765059.SGD":"FTIF - Franklin US Opportunities A Acc SGD","LU0096364046.USD":"CT (LUX) I AMERICAN \"DU\" (USD) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","LU1623119135.USD":"Natixis Mirova Global Sustainable Equity R-NPF/A USD","LU0198837287.USD":"UBS (LUX) EQUITY SICAV - USA GROWTH \"P\" (USD) ACC","LU0061475181.USD":"THREADNEEDLE (LUX) AMERICAN \"AU\" (USD) ACC","NVO":"诺和诺德","LU1064131342.USD":"Fullerton Lux Funds - Global Absolute Alpha A Acc USD","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","LU0882574139.USD":"富达环球消费行业基金A ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4588":"碎股","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","LU0943347566.SGD":"安联收益及增长平衡基金AM H2-SGD","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0238689110.USD":"贝莱德环球动力股票基金","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0109391861.USD":"富兰克林美国机遇基金A Acc","LU0417517546.SGD":"Allianz US Equity Cl AT Acc SGD","LU0385154629.USD":"贝莱德营养科学基金A2","BK4581":"高盛持仓","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0094547139.USD":"abrdn SICAV I - GLOBAL SUSTAINABLE EQUITY FUND \"A\" (USD) ACC"},"translate_title":"Near complete prevention! New breakthrough in Eli Lilly's \"magic medicine for weight loss\": diabetes risk drops by 94%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1,"NVO":0.6},"content_text":"当地时间周二，礼来公司（Eli Lilly）在糖尿病和肥胖治疗领域取得了令人瞩目的进展，其研发的减肥药替尔泊肽(tirzepatide)在临床试验中显示出显著的疗效：与安慰剂相比，替尔泊肽将糖尿病前期、肥胖或超重的成年人患2型糖尿病的风险降低了94%。消息影响下，截至发稿，礼来涨超4%，竞争对手诺和诺德(NVO.US)下跌0.16%。糖尿病风险锐减94%据悉，这项名为SURMOUNT-1的研究，涉及1032名糖尿病前期、肥胖或超重的成年人，经过长达三年的治疗期和随后的17周非治疗期的观察，结果显示，与安慰剂相比，使用tirzepatide的患者体重平均下降了22.9%，而安慰剂组仅下降了2.1%。更引人注目的是，这些患者的2型糖尿病风险降低了94%，即使在停药后的随访期间，这一风险仍然比安慰剂组低88%。据该公司称，这是迄今为止完成的最长的药物研究。尽管该药物在市场上相对较新，但其商业潜力已经显现，去年为公司带来了53.4亿美元的销售额。分析师预计，今年tirzepatide的销售额可能接近180亿美元。礼来公司并未止步于此，正在积极探索tirzepatide在治疗与肥胖相关的多种疾病中的潜力，如心脏病、睡眠呼吸暂停和阿尔茨海默病。这不仅可能扩大患者群体，还有助于获得更广泛的保险覆盖范围。此外，该公司还强调了肥胖症的全球影响，指出近9亿成年人面临肥胖症并发症的风险。在安全性方面，tirzepatide的副作用主要为胃肠道反应，通常为轻度至中度，这为患者提供了一个相对安全的治疗选择。礼来公司计划将这些结果提交至同行评审期刊发表，并在即将到来的医学会议上进行展示，此前已公布了该试验72周的减肥结果。然而，这项研究的成功并非没有挑战。此前，7月外媒消息，两年前，只有四分之一的美国患者服用了诺和诺德的Wegovy或Ozempic来减肥，他们仍在服用这些受欢迎的药物。这表明，尽管减肥药物在减少糖尿病风险方面显示出潜力，但患者的长期依从性仍然是一个问题。业绩方面，礼来公司第二季度业绩亮眼，营收和利润均超市场预期，主要得益于其减肥药销量的大幅增长。财报显示，第二季度营收达到113.03亿美元，同比增长36%，净利润29.67亿美元，同比增长68%。其中，糖尿病药物Mounjaro营收30.9亿美元，减肥药物Zepbound营收12.4亿美元，均超出预期。受此影响，礼来上调了全年营收指引至454亿至466亿美元。股价近来也随之上涨，目前市值已超过9000亿美元。市场分析认为，礼来在减肥药市场的强劲表现使其有望赶超竞争对手诺和诺德。","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.28.3","shortVersion":"4.28.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460888376"}